-
Wall Street Analysts Say These 5 Stocks Are A Buy As The World Prepares For The Post-COVID-19 Era
Monday, November 23, 2020 - 4:47am | 998Read More...From escalating tensions between the U.S. and China, the highly infectious coronavirus pandemic outbreak, and the 2020 presidential Election, this year has turned into a rollercoaster ride for investors. Forced lockdowns weighed down industries like the oil & gas sector, retail businesses,...
-
Conatus Pharma Could Nearly Quadruple, According To H.C. Wainwright Targets
Tuesday, September 22, 2015 - 12:49pm | 298Read More...The share price of Conatus Pharmaceuticals, Inc. (NASDAQ: CNAT) has declined 30.77 percent year-to-date. HC Wainwright’s Ed Arce has initiated coverage of Conatus Pharmaceuticals with a Buy rating and price target of $15. Arce believes that the company’s first-in-class oral...
-
Non-Opioid Therapeutics And Significant Pain Treatments Make For A Buy Rating
Wednesday, September 2, 2015 - 10:58am | 309Read More...The share price of Recro Pharma Inc (NASDAQ: REPH) has surged more than 356 percent year-to-date. Ching-Yi Lin of HC Wainwright & Co has initiated coverage of Recro Pharma with a Buy rating and price target of $19. The company has two promising late-stage products that have...
-
NephroGenex: A Significant Unmet Medical Need
Tuesday, September 1, 2015 - 9:45am | 273Read More...NephroGenex, Inc. (NASDAQ: NRX) has seen a 44.76 percent decline in its share price over the past six months. Yi Chen of HC Wainwright & Co has initiated coverage of NephroGenex with a Buy rating and price target of $9. Chen believes that the stock is undervalued at present, given...
-
H.C. Wainwright Starts Energy Focus At Buy, Notes Strong LED Growth Potential
Thursday, June 25, 2015 - 9:25am | 331Read More...In a report published Thursday, HC Wainwright analyst Carter Driscoll initiated coverage of Energy Focus Inc (NASDAQ: EFOI) with a Buy rating and $11 price target. The analyst believes that the company has almost completed its strategic turnaround and is well positioned for strong growth going...
-
Ur-Energy Started At Buy By H.C. Wainwright, Notes 'Strong' Uranium Project Pipeline
Friday, June 19, 2015 - 8:27am | 332Read More...In a report published Friday, HC Wainwright analyst Heiko F. Ihle initiated coverage of Ur-Energy Inc. (USA) (NYSE: URG) with a Buy rating and price target of $2.10. The company has a robust pipeline of assets in the development stage. Ur-Energy owns a processing facility, Lost Creek, in Wyoming,...
-
HC Wainwright: Time To Buy Gold Standard Ventures, It Has 'The Right Geology, The Right Location'
Tuesday, June 16, 2015 - 8:08am | 271Read More...In a report published Tuesday, HC Wainwright analyst Heiko F. Ihle initiated coverage of Gold Standard Ventures Corp. (NYSEMKT: GSV) with a Buy rating and a price target of $1.10. The company is currently focused on advancing its Railroad-Pinion project. "The project is located at the southern...
-
HC Wainwright: Inuvo 'Hitting Its Stride,' Initiating With Buy
Tuesday, May 19, 2015 - 10:23am | 231Read More...In a report published Tuesday, analysts at HC Wainwright & Co initiated coverage of Inuvo Inc (NYSE: INUV) with a Buy rating and price target of $4. The company offers a robust combination of content, technology and marketing. Inuvo is an online advertising and publishing company that "...
-
XTL Biopharmaceuticals Aims To Tame Lupus, HC Wainwright Initiates At Buy
Friday, May 8, 2015 - 9:35am | 236Read More...In a report published Friday, analyst Swayampakula Ramakanth of HC Wainwright & Co initiated coverage of XTL Biopharmaceuticals Ltd (NASDAQ: XTLB) with a Buy rating and a price target of $6. Of the three product candidates the company currently has, Edratide is a lead product and targets a...
-
Why Nokia-Alcatel Lucent Deal Could Be A 'Game Changer' For DragonWave
Wednesday, April 15, 2015 - 10:54am | 362Read More...In a report published Wednesday, H.C. Wainwright & Co. analyst Kevin Dede argued that Nokia Corporation (NYSE: NOK) "swallowing" Alcatel Lucent SA (NYSE: ALU) could be a "game changer" for DragonWave, Inc. (USA) (NASDAQ: DRWI). Shares are Buy rated with a $1.50 price...
